Burden of systemic lupus erythematosus in Taiwan: a population-based survey

Yeh, Kuo Wei; Yu, Cunqian; Chan, Pei-Ying S.; Horng, Jorng-Tzong; Huang, Jing‐Long

doi:10.1007/s00296-012-2643-6

Cited by 54 publications

(45 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent large hospital‐based study in the UK showed significant association between SLE and sarcoidosis (aOR, 8.33; 95% CI, 2.71–19.4) . In our study, the prevalence of SLE in the control group was consistent with a previous nationwide survey in Taiwan, which suggested that the matched control group we sampled could represent the population. Our analysis showed that sarcoidosis patients could have been likely to develop SLE (aOR, 2.98), but the small case number rendered the statistical evaluation insignificant.…”

Section: Discussionsupporting

confidence: 90%

“…The remaining two diseases, SLE and psoriasis, were not uncommon in Taiwan with prevalence of 97.5 and 278.3 per 100 000 population, respectively . There are increasing reports supporting the coexistence of SLE and sarcoidosis with approximately 30 cases reported in the English‐language published work, including four Asian cases .…”

Section: Discussionmentioning

confidence: 99%

“…The remaining two diseases, SLE and psoriasis, were not uncommon in Taiwan with prevalence of 97.5 and 278.3 per 100 000 population, respectively. 41,42 There are increasing reports supporting the coexistence of SLE and sarcoidosis with approximately 30 cases reported in the English-language published work, including four Asian cases. 9,11,15,16,[20][21][22]43 A recent large hospital-based study in the UK showed significant association between SLE and sarcoidosis (aOR, 8.33; 95% CI, 2.71-19.4).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case–control study in Taiwan

Chung

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

The association between sarcoidosis and autoimmune comorbidities has been reported, however, it has seldom been confirmed by a large nationwide study. Our study aimed to clarify the association between sarcoidosis and autoimmune comorbidities in the Taiwanese. A total of 1237 patients with sarcoidosis and 4948 age- and sex-matched control subjects were selected from the National Health Insurance Research Database of Taiwan from 1997 to 2010. Multiple logistic regressions were performed to calculate the odds of comorbidities between the two groups. The prevalence of sarcoidosis was 2.17/100 000 individuals in Taiwan. Sarcoidosis patients tended to run a higher risk of autoimmune comorbidities than the control group (17.6% vs 9.4%, P < 0.05). Autoimmune thyroid disease (adjusted odd ratio [aOR], 1.32; 95% confidence interval [CI], 1.05-1.64), Sjögren's syndrome (aOR, 11.6; 95% CI, 4.36-31.0) and ankylosing spondylitis (aOR, 3.80; 95% CI, 2.42-5.97) were significantly associated with sarcoidosis. The sex-stratified analyses were carried out to demonstrate a significant association of sarcoidosis with ankylosing spondylitis in both sexes, but with autoimmune thyroid disease in male patients and with Sjögren's syndrome female patients, respectively. Besides, the diagnosis of the autoimmune comorbidities strongly associated with sarcoidosis tended to be established after that of sarcoidosis. This study demonstrated that patients with sarcoidosis tended to have autoimmune thyroid disease, Sjögren's syndrome and ankylosing spondylitis, and the diagnosis of sarcoidosis usually preceded that of associated comorbidities. Clinicians should be alert to autoimmune comorbidities in patients with sarcoidosis.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case–control study in Taiwan

Chung

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The NHIRD has been described in-depth in our previous studies [6, 21–26]. In short, Taiwan National Health Insurance (NHI) program commenced on 1 March 1995.…”

Section: Methodsmentioning

confidence: 99%

Population-based cohort study on the risk of malignancy in East Asian children with Juvenile idiopathic arthritis

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundTo investigate the association and magnitude of risk between JIA, its associated treatment and cancer development in Taiwanese children.MethodsNationwide population-based 1:4 age- and gender-matched retrospective cohort study was designed using the National Health Insurance Research Database of Taiwan. A cohort of 2,892 children <16 years old with JIA was formed as well as a non-JIA cohort of 11,568 in year 2003 to 2005. They were followed up till a diagnosis of malignancy or up to 8 years until 2010. Relative risk (RR), incidence rate ratio (IRR), and adjusted hazard ratio (aHR) of developing malignancy were calculated.ResultsThe female to male ratio was 0.79:1. There were 3 cases of incident cancer in the “MTX use, biologics-naïve” group, only 1 in the anti-TNF biologics-containing group and 29 in the “both MTX- and biologics-naïve” group, in comparison, there were 50 cases of cancer in the non-JIA comparator group. During a 16114.16 patient-years follow-up, the RR and IRR for developing a malignancy in both methotrexate- and anti-tumor necrosis factor (TNF) biologics-naïve JIA children were 2.75 (95% confidence interval, 1.75 – 4.32) and 3.21 (2.01 – 5.05), respectively. For leukemia, the IRR was 7.38 (2.50 – 22.75); lymphoma, 8.30 (1.23 – 69.79); and soft tissue sarcoma, 11.07 (0.84 – 326.4). The IRR of other cancers was 2.08 (1.11 – 3.71). The aHR on cancer risk was 3.14 (1.98 – 4.98) in methotrexate- and biologics-naïve group. There were no statistically significant increased risk in JIA patients treated with methotrexate and/or anti-TNF biologics.ConclusionsCompared with children without JIA, children with JIA have 3-fold increase of risk on malignancy in East Asia. Seemingly neither methotrexate nor anti-TNF biologics increases the risk further.

show abstract

“…With early diagnosis and enhanced treatment strategies, the survival of patients with systemic lupus erythematosus (SLE) has improved dramatically in the last 50 years (Doria, Gatto, Zen, Iaccarino, & Punzi, ). However, China, the largest country in the Asia‐Pacific area, has a relatively higher prevalence rate than other countries (Mok, ; Yeh, Yu, Chan, Horng, & Huang, ), and lupus nephritis (LN) is still the most frequent visceral complication of SLE, accounting for increased morbidity (including end‐stage renal disease) and mortality rates (Mok, ). Above all, it is important to explore the mechanism of LN and identify personalized treatment options.…”

Section: Introductionmentioning

confidence: 99%

HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis

Feng

Yang

Tian

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus. Patients with LN mostly die of sclerosing glomerulonephritis and renal failure. The inhibition of glomerular mesangial matrix deposition is an efficient method to restrict the progress of renal injury. By recognizing and binding extracellular and intracellular ligands, Toll‐like receptor 2 (TLR2) contributes to the pathogenesis of most immune diseases. However, the relationship between TLR2 and LN is still unknown. Our previous studies confirmed that high‐mobility group box 1 (HMGB1), an important ligand of TLR2, promotes the progression of LN by inducing the proliferation of glomerular mesangial cells. However, whether or not HMGB1 participates in the pathogenesis of glomerular mesangial matrix deposition in LN remains unknown. In this study, we observed the upregulated expression of TLR2 in the glomeruli of LN patients and MRL/lpr mice. The inhibition of either TLR2 or HMGB1 inhibited the release of fibronectin and the activation of the MyD88/NF‐κB pathway in mesangial cells cultured with LN plasma. In addition, both TLR2‐ and HMGB1‐deficient mice showed reduced 24 hr urine protein levels and improved glomerular histological changes and sclerosis levels. These results indicate that TLR2 regulates glomerular mesangial matrix deposition in LN through the activation of the MyD88/NF‐κB pathway by binding to HMGB1.

show abstract

Burden of systemic lupus erythematosus in Taiwan: a population-based survey

Cited by 54 publications

References 18 publications

Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case–control study in Taiwan

Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case–control study in Taiwan

Population-based cohort study on the risk of malignancy in East Asian children with Juvenile idiopathic arthritis

HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis

Contact Info

Product

Resources

About